OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$2.65
0.10 (3.92%)
▲
5d:
+21.56%
30d:
+69.87%
90d:
+54.97%
WAIT
LOW Confidence
Analysis Updated: May 22, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OABI is 23.8% above its trading range ($2.14). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OABI is 23.8% above its trading range ($2.14). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $2.65, which is considered extended relative to its 30-day fair value range of $1.32 to $2.14.
Technical Outlook: Technically, OABI is showing sideways momentum. The price is approaching resistance at $2.61. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: OABI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.33 (+176.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OABI is showing sideways momentum. The price is approaching resistance at $2.61. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: OABI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.33 (+176.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.32 -
$2.14
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+23.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 176.7% below Wall St target ($7.33)
- WARNING: Recommendation downgraded due to 23.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$1.32 -
$2.14
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.52
Resistance Level
$2.61
Current Trend
Sideways
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.22
Wall Street Target
$7.33
(+176.7%)
Revenue Growth (YoY)
247.3%
Profit Margin
-187.6%
Share & Embed Analysis
Last updated: May 25, 2026 4:51 PM ET
Data refreshes hourly during market hours. Next update: 5:51 PM
Data refreshes hourly during market hours. Next update: 5:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 48 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 49 HOLD |
